Vanguard Capital Management
VVOS icon

Vanguard Capital Management’s Vivos Therapeutics VVOS Stock Holding History

Vanguard Capital Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.6K Sell
60,629
-212,700
-78% -$167K ﹤0.01% 3989
2026
Q1 		$323K Buy
+273,329
New +$438K ﹤0.01% 3740

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's VVOS Position: Q2 2026 in Review

Vanguard Capital Management reduced its Vivos Therapeutics (VVOS) stake by 78% in Q2 2026, selling an estimated $167K and leaving 60,629 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3989.

Vanguard Capital Management first reported a position in VVOS in Q1 2026 and has held it in 2 quarters since. The position peaked at $323K in Q1 2026. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

  • Vanguard Capital Management held 60,629 shares of Vivos Therapeutics worth $27.6K as of Q2 2026.
  • Vanguard Capital Management sold 212,700 Vivos Therapeutics shares in Q2 2026, an estimated $167K.
  • Vivos Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3989 holding.
  • Vanguard Capital Management first reported a position in Vivos Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Vivos Therapeutics position peaked at $323K in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.